BioCentury
ARTICLE | Financial News

Bioniz raises $13M in series A round

August 1, 2016 7:00 AM UTC

Bioniz Therapeutics Inc. (Irvine, Calif.) raised $13 million in a series A round co-led by the Takeda Ventures unit of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and David Pyott, the former chairman and CEO of Allergan Inc. (NYSE:AGN). Joe Kiani and Cota Capital also participated.

Bioniz said it expects to begin a Phase I study "shortly" of lead candidate BNZ-1 in collaboration with NIH. It plans to develop the selective inhibitor of interleukin-2 (IL-2), IL-9 and IL-15 to treat human T cell lymphotropic virus type 1 (HTLV-1) associated myelopathy and some T cell leukemias. ...